244 related articles for article (PubMed ID: 26589767)
21. Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer.
Bouanene H; Hadj Kacem H; Ben Fatma L; Ben Limem H; Ben Ahmed S; Yakoub S; Miled A
Pathol Oncol Res; 2011 Jun; 17(2):295-9. PubMed ID: 21046495
[TBL] [Abstract][Full Text] [Related]
22. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
23. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.
McLemore MR; Aouizerat B
Biol Res Nurs; 2005 Apr; 6(4):262-7. PubMed ID: 15788735
[TBL] [Abstract][Full Text] [Related]
24. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
26. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.
Ehlen TG; Hoskins PJ; Miller D; Whiteside TL; Nicodemus CF; Schultes BC; Swenerton KD
Int J Gynecol Cancer; 2005; 15(6):1023-34. PubMed ID: 16343178
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Taylor DD; Gercel-Taylor C; Parker LP
Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
[TBL] [Abstract][Full Text] [Related]
29. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
30. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
31. A novel monoclonal antibody to a defined peptide epitope in MUC16.
Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
[TBL] [Abstract][Full Text] [Related]
32. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.
Möbus VJ; Baum RP; Bolle M; Kreienberg R; Noujaim AA; Schultes BC; Nicodemus CF
Am J Obstet Gynecol; 2003 Jul; 189(1):28-36. PubMed ID: 12861134
[TBL] [Abstract][Full Text] [Related]
33. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
Yin BW; Dnistrian A; Lloyd KO
Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
[TBL] [Abstract][Full Text] [Related]
34. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
35. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients.
Sakahara H; Saga T; Onodera H; Yao Z; Nakamoto Y; Zhang M; Sato N; Nakada H; Yamashina I; Endo K; Konishi J
Jpn J Cancer Res; 1997 Sep; 88(9):895-9. PubMed ID: 9369938
[TBL] [Abstract][Full Text] [Related]
36. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.
Chatterjee M; Dyson G; Levin NK; Shah JP; Morris R; Munkarah A; Tainsky MA
Cancer Biomark; 2012; 11(2-3):59-73. PubMed ID: 23011153
[TBL] [Abstract][Full Text] [Related]
37. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
38. Construction of the single-chain Fv from 196-14 antibody toward ovarian cancer-associated antigen CA125.
Hashimoto Y; Tanigawa K; Nakashima M; Sonoda K; Ueda T; Watanabe T; Imoto T
Biol Pharm Bull; 1999 Oct; 22(10):1068-72. PubMed ID: 10549857
[TBL] [Abstract][Full Text] [Related]
39. Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification.
Zhang H; Yang Y; Wang Y; Gao X; Wang W; Liu H; He H; Liang Y; Pan K; Wu H; Shi J; Xue H; Liang L; Cai Z; Fan Y; Zhang Y
J Ovarian Res; 2015 Mar; 8():19. PubMed ID: 25886959
[TBL] [Abstract][Full Text] [Related]
40. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]